[Federal Register Volume 81, Number 28 (Thursday, February 11, 2016)]
[Notices]
[Pages 7392-7394]
[FR Doc No: 2016-02729]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-77074; File No. SR-NYSEMKT-2016-14]

Self-Regulatory Organizations; NYSE MKT LLC; Notice of Filing and
Immediate Effectiveness of Proposed Rule Change Amending Supplementary
Material .10 to Rule 103B--Equities To Provide That Any Senior Official
of a Listed Company With the Rank of Corporate Secretary or Higher Can
Sign the Written Request of a Listed Company Seeking To Change Its
Designated Market Maker Unit

February 5, 2016.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on January 27, 2016, NYSE MKT LLC (the ``Exchange'' or ``NYSE MKT'')
filed with the Securities and Exchange Commission (``SEC'' or
``Commission'') the proposed rule change as described in Items I and II
below, which Items have been prepared by the Exchange. The Commission
is publishing this notice to solicit comments on the proposed rule
change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend Supplementary Material .10 to Rule
103B--Equities to provide that any senior official of a listed company
with the rank of Corporate Secretary or higher can sign the written
request of a listed company seeking to change its designated market
maker (``DMM'') unit. The proposed rule change is available on the
Exchange's Web site at www.nyse.com, at the principal office of the
Exchange, and at the Commission's Public Reference Room.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the self-regulatory organization
included statements concerning the purpose of, and basis for, the
proposed rule change and discussed any comments it received on the
proposed rule change. The text of those statements may be examined at
the places specified in Item IV below. The Exchange has prepared
summaries, set forth in sections A, B, and C below,

of the most significant parts of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and the
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Exchange proposes to amend Supplementary Material .10 to Rule
103B--Equities to provide that any senior official of a listed company
with the rank of Corporate Secretary or higher can sign the written
request of a listed company seeking to change its DMM unit required by
that provision.
    Supplementary Material .10 to Rule 103B--Equities establishes a
process to be followed by any listed company wishing to change to a new
DMM unit. The rule provides that a listed company wishing to change DMM
units must file with the Corporate Secretary of the Exchange a written
notice (the ``Issuer Notice''), signed by the company's chief executive
officer. The Issuer Notice is required to indicate the specific issues
prompting this request. It has been the Exchange's experience that
companies have occasionally found it burdensome to obtain the signature
of their CEO for purposes of submitting an Issuer Notice and that this
requirement has caused an undesirable delay when companies are making
their submissions. We also note that this requirement is inconsistent
with the provisions of Rule 103B--Equities in relation to an issuer's
initial selection of a DMM, which provides that any senior official
with the rank of Corporate Secretary or higher (or, in the case of a
structured product listing, a senior officer of the issuer) can sign
the notice in which a listed company informs the Exchange of its
initial selection of a DMM unit. It has been the Exchange's experience
that a senior officer other than the chief executive officer often
manages the DMM relationship on behalf of the listed company and has
authority to take action in relation to that relationship. We also note
that the NYSE recently amended its parallel provision (Section 806.01
of the NYSE's Listed Company Manual) to address this issue by providing
that an Issuer Notice may be signed by an official of the listed
company with the rank of Corporate Secretary or higher.\3\
Consequently, we propose to amend Supplementary Material .10 to Rule
103B--Equities to make the same change.
---------------------------------------------------------------------------

    \3\ See Securities Exchange Act Release No. 76591 (December 8,
2015), 80 FR 77392 (December 14, 2015) (SR-NYSE-2015-63).
---------------------------------------------------------------------------

2. Statutory Basis
    The Exchange believes that the proposed rule change is consistent
with Section 6(b) \4\ of the Act, in general, and furthers the
objectives of Section 6(b)(5) of the Act,\5\ in particular in that it
is designed to promote just and equitable principles of trade, to
foster cooperation and coordination with persons engaged in regulating,
clearing, settling, processing information with respect to, and
facilitating transactions in securities, to remove impediments to and
perfect the mechanism of a free and open market and a national market
system, and, in general, to protect investors and the public interest
and is not designed to permit unfair discrimination between customers,
issuers, brokers, or dealers. The Exchange believes that the proposed
amendment is consistent with the investor protection objectives of
Section 6(b)(5) because it is designed to ensure that listed companies
are able to expeditiously change their DMM unit when senior management
of the listed company believes it is desirable to do so. An effective
relationship between the listed company and the DMM is important to the
maintenance of a high quality market for the company's securities and
is therefore in the interests of investors.
---------------------------------------------------------------------------

    \4\ 15 U.S.C. 78f(b).
    \5\ 15 U.S.C. 78f(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The Exchange does not believe that the proposed rule change will
impose any burden on competition that is not necessary or appropriate
in furtherance of the purpose of the Act. The proposed rule change is
designed to permit listed companies to apply for a change in the DMM
unit allocated to their securities on the basis of a notice signed by
any officer with the title of Corporate Secretary or higher rather than
requiring that it be signed in all cases by the CEO, as is currently
the case. The proposed amendment simply provides more flexibility in
providing the required paperwork and conforms the signing requirements
with respect to the commencement and severing of a listed company's
relationship with its DMM unit, but does not change any of the
substantive rights of the listed company or the DMM unit in any way. As
such, the Exchange does not expect the rule change to have any
significant impact on competition.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    No written comments were solicited or received with respect to the
proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    The Exchange has filed the proposed rule change pursuant to Section
19(b)(3)(A)(iii) of the Act \6\ and Rule 19b-4(f)(6) thereunder.\7\
Because the proposed rule change does not: (i) Significantly affect the
protection of investors or the public interest; (ii) impose any
significant burden on competition; and (iii) become operative for 30
days from the date on which it was filed, or such shorter time as the
Commission may designate, if consistent with the protection of
investors and the public interest, the proposed rule change has become
effective pursuant to Section 19(b)(3)(A) of the Act \8\ and Rule 19b-
4(f)(6) thereunder.\9\
---------------------------------------------------------------------------

    \6\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \7\ 17 CFR 240.19b-4(f)(6).
    \8\ 15 U.S.C. 78s(b)(3)(A).
    \9\ 17 CFR 240.19b-4(f)(6). In addition, Rule 19b-4(f)(6)(iii)
requires the Exchange to give the Commission written notice of the
Exchange's intent to file the proposed rule change, along with a
brief description and text of the proposed rule change, at least
five business days prior to the date of filing of the proposed rule
change, or such shorter time as designated by the Commission. The
Exchange has satisfied this requirement.
---------------------------------------------------------------------------

    A proposed rule change filed under Rule 19b-4(f)(6) \10\ normally
does not become operative prior to 30 days after the date of the
filing. However, pursuant to Rule 19b-4(f)(6)(iii),\11\ the Commission
may designate a shorter time if such action is consistent with the
protection of investors and the public interest. The Exchange has asked
the Commission to waive the 30-day operative delay so that the proposed
rule change may become operative immediately. The Exchange believes
that providing greater flexibility in the preparation of the paperwork
needed to request a change of DMM unit is in the interests of investors
as it is important to the maintenance of a high quality market for an
issuer's stock that the issuer has a good relationship with its DMM. As
the Exchange notes in its filing, the proposal would better conform the
process for changing a DMM to that which is used for initially
selecting a DMM. In particular, the officer's signature that would be
required to change a company's DMM

must be that of a senior official at the company with a rank of
Corporate Secretary or above. Based on the foregoing, the Commission
believes that waiving the 30-day operative delay is consistent with the
protection of investors and the public interest. For this reason, the
Commission hereby waives the 30-day operative delay and designates the
proposal operative upon filing.\12\
---------------------------------------------------------------------------

    \10\ 17 CFR 240.19b-4(f)(6).
    \11\ 17 CFR 240.19b-4(f)(6)(iii).
    \12\ For purposes only of waiving the 30-day operative delay,
the Commission has considered the proposed rule's impact on
efficiency, competition, and capital formation. See 15 U.S.C.
78c(f).
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act. If the Commission
takes such action, the Commission shall institute proceedings to
determine whether the proposed rule change should be approved or
disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml); or
     Send an email to<EMAIL_ADDRESS>Please include
File Number SR-NYSEMKT-2016-14 on the subject line.

Paper Comments

     Send paper comments in triplicate to Secretary, Securities
and Exchange Commission, 100 F Street NE., Washington, DC 20549-1090.

All submissions should refer to File Number SR-NYSEMKT-2016-14. This
file number should be included on the subject line if email is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for Web site viewing and
printing in the Commission's Public Reference Room, 100 F Street NE.,
Washington, DC 20549 on official business days between the hours of
10:00 a.m. and 3:00 p.m. Copies of the filing also will be available
for inspection and copying at the principal office of the Exchange. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-NYSEMKT-2016-14, and should
be submitted on or before March 3, 2016.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\13\
---------------------------------------------------------------------------

    \13\ 17 CFR 200.30-3(a)(12), (59).
---------------------------------------------------------------------------

Brent J. Fields,
Secretary.
[FR Doc. 2016-02729 Filed 2-10-16; 8:45 am]
 BILLING CODE 8011-01-P


[Federal Register: March 19, 2008 (Volume 73, Number 54)]
[Notices]
[Page 14826]
[DOCID:fr19mr08-71]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[USCG-2008-0188]

National Offshore Safety Advisory Committee

AGENCY: Coast Guard, DHS.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The National Offshore Safety Advisory Committee (NOSAC) will
meet to discuss various issues relating to offshore safety and
security. The meeting will be open to the public.

DATES: NOSAC will meet on Friday, April 18, 2008, from 9 a.m. to 3 p.m.
The meeting may close early if all business is finished. Written
material and requests to make oral presentations should reach the Coast
Guard on or before April 4, 2008. Requests to have a copy of your
material distributed to each member of the committee should reach the
Coast Guard on or before April 4, 2008.

ADDRESSES: NOSAC will meet in room 2415 of the Coast Guard Headquarters
Bldg., 2100 Second Street, SW., Washington, DC. Send written material
and requests to make oral presentations to Commander J.M. Cushing,
Commandant (CG-5222), U.S. Coast Guard Headquarters, 2100 Second Street
SW., Washington, DC 20593-0001. This notice is available on our online
docket, USCG-2008-0188, at http://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Commander J.M. Cushing, Executive
Director of NOSAC, or Mr. Jim Magill, Assistant Executive Director,
telephone<PHONE_NUMBER>, fax<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: Notice of the meeting is given under the
Federal Advisory Committee Act, 5 U.S.C. App. (Pub. L. 92-463).

Agenda of Meeting

    The agenda for the April 18, 2008 committee meeting includes the
following:
    (1) Report on issues concerning the International Maritime
Organization (IMO) and the International Organization for
Standardization.
    (2) Revision of 46 CFR, Subchapter V, Subpart B--Commercial Diving
Operations.
    (3) MARPOL Annex II Implementation for Existing Offshore Supply
Vessels (OSVs).
    (4) Revision of IMO Mobile Offshore Drilling Units (MODU) Code.
    (5) Sandblasting standard for OCS facilities.
    (6) Evacuation of Injured Workers from remote Drilling and
Production Facilities.
    (7) Transportation Worker Identification Credential (TWIC) impact
on offshore facilities.
    (8) Revision of 33 CFR, Subchapter N, Outer Continental Shelf
Activities.

Procedural

    The meeting is open to the public. Please note that the meeting may
close early if all business is finished. At the Chair's discretion,
members of the public may make oral presentations during the meeting.
If you would like to make an oral presentation at the meeting, please
notify the Executive Director no later than April 4, 2008. Written
material for distribution at the meeting should reach the Coast Guard
no later than April 4, 2008. If you would like a copy of your material
distributed to each member of the committee in advance of the meeting,
please submit 25 copies to the Executive Director no later than April
4, 2008.

Information on Services for Individuals With Disabilities

    For information on facilities or services for individuals with
disabilities or to request special assistance at the meeting, contact
the Executive Director as soon as possible.

    Dated: March 12, 2008.
J.G. Lantz,
Director of Commercial Regulations and Standards.
 [FR Doc. E8-5563 Filed 3-18-08; 8:45 am]

BILLING CODE 4910-15-P


[Federal Register Volume 81, Number 22 (Wednesday, February 3, 2016)]
[Notices]
[Pages 5764-5766]
[FR Doc No: 2016-01888]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-D-4848]

Human Factors Studies and Related Clinical Study Considerations
in Combination Product Design and Development; Draft Guidance for
Industry and Food and Drug Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a draft guidance for industry and FDA staff
entitled ``Human Factors Studies and Related Clinical Study
Considerations in Combination Product Design and Development.'' This
document provides guidance to industry and FDA staff on the underlying
principles of human factors (HF) studies during the development of
combination products. Combination products are comprised of any
combination of a drug and a device; a device and a biological product;
a biological product and a drug; or a drug, a device, and a biological
product.

DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comments on
this draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by May 3, 2016.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to http://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on http://www.regulations.gov.

     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2015-D-4848 for ``Human Factors Studies and Related Clinical Study
Considerations in Combination Product Design and Development.''
Received comments will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at http://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on http://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
    Submit written requests for single copies of the draft guidance to
the Office of Combination Products, Food and Drug Administration, Bldg.
32, Rm. 5129, 10903 New Hampshire Ave., Silver Spring, MD 20993. Send
one self-addressed adhesive label to assist that office in processing
your requests. See the SUPPLEMENTARY INFORMATION section for electronic
access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Patricia Love, Deputy Director, Office
of Combination Products, Office of Special Medical Programs, Office of
Medical Products and Tobacco, Office of the Commissioner, Food and Drug
Administration, at<EMAIL_ADDRESS>or<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    FDA is announcing the availability of a draft guidance for industry
and FDA staff entitled ``Human Factors Studies and Related Clinical
Study Considerations in Combination Product Design and Development.''
This document provides guidance to industry and FDA staff on the
underlying principles of HF studies during the development of
combination products as defined under 21 CFR part 3. This draft
guidance describes Agency recommendations regarding HF information in a
combination product investigational or marketing application. It
clarifies the different types of HF studies, offers recommendations for
timing and sequencing of HF studies, and discusses how HF studies
contribute to assuring that combination products are safe and effective
for the intended users, uses and environments. The draft guidance also
addresses process considerations for HF information in investigational
or marketing applications to promote development and timely review of
safe and effective combination products. In addition, the draft
guidance describes how HF studies relate to other clinical studies.
    This draft guidance refers to two existing guidance documents that
provide related information on HF considerations. These are Guidance
for Industry and FDA Staff, ``Applying Human Factors and Usability
Engineering to Optimize Medical Device Design,'' accessible at http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM259760.pdf and Draft Guidance ``Safety
Considerations for Product Design to Minimize Medication Errors,''
accessible at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM331810.pdf.
    This draft guidance provides examples of the use of HF studies for
different types of combination products in different clinical settings.
FDA welcomes comments to the docket on other examples of combination
products and why they may or may not need HF studies. Additionally FDA
seeks comments on what challenges and development risks may arise
depending upon whether HF studies are conducted before, in parallel to,
or after major clinical studies.

II. Significance of Guidance

    This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on ``Human
Factors Studies and Related Clinical Study Considerations in
Combination Product Design and Development.'' It does not establish any
rights for any person and is not binding on FDA or the public. You can
use an alternative approach if it satisfies the requirements of the
applicable statutes and regulations.

III. Electronic Access

    Persons with access to the Internet may obtain the document at
http://www.fda.gov/RegulatoryInformation/Guidances/ucm122047.htm,
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm, or http://www.regulations.gov.

IV. Paperwork Reduction Act of 1995

    This draft guidance refers to currently approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in

21 CFR part 314 for NDAs and ANDAs have been approved under OMB control
number 0910-0001. The collections of information in 21 CFR part 601 for
BLAs have been approved under OMB control number 0910-0338. The
collections of information in 21 CFR part 814, subparts B and E, for
PMAs have been approved under OMB control number 0910-0231. The
collections of information in 21 CFR part 814, subpart H, for
humanitarian device exemption applications have been approved under OMB
control number 0910-0332. The collections of information in 21 CFR part
807, subpart E, for 510(k) notifications have been approved under OMB
control number 0901-0120. The collections of information in 21 CFR part
312 for INDs have been approved under OMB control number 0910-0014. The
collections of information in 21 CFR part 812 for IDEs have been
approved under OMB control number 0910-0078. The collections of
information in 21 CFR part 820 for the quality system regulation have
been approved under OMB control number 0910-0073.

    Dated: January 28, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-01888 Filed 2-2-16; 8:45 am]
 BILLING CODE 4161-01-P


[Federal Register: December 30, 2008 (Volume 73, Number 250)]
[Notices]
[Page 79876]
[DOCID:fr30de08-79]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket Nos. EL09-22-000; QF93-159-007]

Glenns Ferry Cogeneration Partners, Ltd.; Notice of Filing

December 19, 2008.
    Take notice that on December 15, 2008, Black Hills Corporation, on
behalf of Glenns Ferry Cogeneration Partners, Ltd. filed a petition for
recertification as a qualifying cogeneration facility, pursuant to
section 292.205(a) of the Commission's Regulations, and a limited
waiver of the Commission's qualifying facility operating and efficiency
standard requirements, pursuant to section 292.205(c), for year 2008.
    Any person desiring to intervene or to protest this filing must
file in accordance with Rules 211 and 214 of the Commission's Rules of
Practice and Procedure (18 CFR 385.211, 385.214). Protests will be
considered by the Commission in determining the appropriate action to
be taken, but will not serve to make protestants parties to the
proceeding. Any person wishing to become a party must file a notice of
intervention or motion to intervene, as appropriate. Such notices,
motions, or protests must be filed on or before the comment date. On or
before the comment date, it is not necessary to serve motions to
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper using the ``eFiling'' link at http://
www.ferc.gov. Persons unable to file electronically should submit an
original and 14 copies of the protest or intervention to the Federal
Energy Regulatory Commission, 888 First Street, NE., Washington, DC
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the
``eLibrary'' link and is available for review in the Commission's
Public Reference Room in Washington, DC. There is an ``eSubscription''
link on the Web site that enables subscribers to receive e-mail
notification when a document is added to a subscribed docket(s). For
assistance with any FERC Online service, please e-mail
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For
TTY, call<PHONE_NUMBER>.
    Comment Date: 5 p.m. Eastern Time on January 14, 2009.

Kimberly D. Bose,
Secretary.
[FR Doc. E8-30927 Filed 12-29-08; 8:45 am]

BILLING CODE 6717-01-P